Non-nucleoside analogue polymerase inhibitors in development.
Non-nucleoside polymerase inhibitors have several limitations including low to moderate potency, a low barrier to resistance, unlikely to cross genotype activity, genotype potency 1b > 1a, and hyperbilirubinemia for 2 of the drugs (tegobuvir and BI-207127). These drugs will have no role in monotherapy and may have only a limited role in triple therapy. They could be part of a quadruple therapy regimen or a triple or quadruple interferon-free regimen. Several issues remain unclear at the time of this review; the role of these compounds including minimal dosing required, safety, and cost remains to be clarified.